Duffy, J. P. et al. Long-term patient outcome and quality of life after liver transplantation: analysis of 20-year survivors. Ann. Surg. 252, 652–661 (2010).
Fleming, K. M., Aithal, G. P., Card, T. R. & West, J. All-cause mortality in people with cirrhosis compared with the general population: a population-based cohort study. Liver Int. 32, 79–84 (2012).
Vilstrup, H. et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver. Hepatology 60, 715–735 (2014).
Hoilat, G. J. et al. Polyethylene glycol versus lactulose in the treatment of hepatic encephalopathy: a systematic review and meta-analysis. BMJ Open Gastroenterol. 8, e000648 (2021).
Rahimi, R. S., Singal, A. G., Cuthbert, J. A. & Rockey, D. C. Lactulose vs polyethylene glycol 3350–electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial. JAMA Intern. Med. 174, 1727–1733 (2014).
Bass, N. M. et al. Rifaximin treatment in hepatic encephalopathy. N. Engl. J. Med. 362, 1071–1081 (2010).
Goh, E. T. et al. L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst. Rev. 5, CD012410 (2018).
Butterworth, R. F. & McPhail, M. J. W. L-Ornithine L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses. Drugs 79, 31–37 (2019).
Gluud, L. L. et al. Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst. Rev. 5, CD001939 (2017).
Bannister, C. A. et al. Natural History of Patients Taking Rifaximin-alpha for Recurrent Hepatic Encephalopathy and Risk of Future Overt Episodes and Mortality: A Post-hoc Analysis of Clinical Trials Data. Clin. Ther. 38, 1081–1089.e1084 (2016).
Holecek, M. Branched-chain amino acid supplementation in treatment of liver cirrhosis: Updated views on how to attenuate their harmful effects on cataplerosis and ammonia formation. Nutrition 41, 80–85 (2017).
Simon-Talero, M. et al. Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis. Gastroenterology 154, 1694–1705.e1694 (2018).
Laleman, W. et al. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology 57, 2448–2457 (2013).
Bajaj, J. S. et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. Hepatology 66, 1727–1738 (2017).
D’Amico, G. et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharm. Ther. 39, 1180–1193 (2014).
Salerno, F., Camma, C., Enea, M., Rossle, M. & Wong, F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 133, 825–834 (2007).
Gines, P. et al. Hepatorenal syndrome. Nat. Rev. Dis. Prim. 4, 23 (2018).
Tandon, P. et al. Relevance of New Definitions to Incidence and Prognosis of Acute Kidney Injury in Hospitalized Patients with Cirrhosis: A Retrospective Population-Based Cohort Study. PLoS One 11, e0160394 (2016).
MacDonald, A. J., Nadim, M. K., Durand, F. & Karvellas, C. J. Acute kidney injury in cirrhosis: implications for liver transplantation. Curr. Opin. Crit. Care 25, 171–178 (2019).
Wong, F. et al. New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. Gastroenterology 145, 1280–1288.e1281 (2013).
European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J. Hepatol. 69, 406–460 (2018).
Gatta, A. et al. A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients. Hepatology 14, 231–236 (1991).
Angeli, P. et al. Tubular site of renal sodium retention in ascitic liver cirrhosis evaluated by lithium clearance. Eur. J. Clin. Invest 20, 111–117 (1990).
Benmassaoud, A. et al. Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis. Cochrane Database Syst. Rev. 1, CD013123 (2020).
Boike, J. R. et al. North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension. Clin. Gastroenterol. Hepatol. 20, 1636–1662.e1636 (2022).
Gines, A. et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 111, 1002–1010 (1996).
Caraceni, P. et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet 391, 2417–2429 (2018).
Caraceni, P., O’Brien, A. & Gines, P. Long-term albumin treatment in patients with cirrhosis and ascites. J. Hepatol. 76, 1306–1317 (2022).
Biggins, S. W. et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 74, 1014–1048 (2021).
Caraceni, P. et al. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. J. Hepatol. 74, 340–349 (2021).
Kim, W. R. et al. MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era. Gastroenterology 161, 1887–1895.e1884 (2021).
Velez, J. C. Q., Petkovich, B., Karakala, N. & Huggins, J. T. Point-of-Care Echocardiography Unveils Misclassification of Acute Kidney Injury as Hepatorenal Syndrome. Am. J. Nephrol. 50, 204–211 (2019).
Allegretti, A. S., Subramanian, R. M., Francoz, C., Olson, J. C. & Cardenas, A. Respiratory events with terlipressin and albumin in hepatorenal syndrome: A review and clinical guidance. Liver Int. 42, 2124–2130 (2022).
Pena Polanco, N., et al. Point of care ultrasound in the treatment of acute kidney injury in patients with cirrhosis. Liver Transpl. (2024). In press.
Bassegoda, O. et al. Development of chronic kidney disease after acute kidney injury in patients with cirrhosis is common and impairs clinical outcomes. J. Hepatol. 72, 1132–1139 (2020).
de Franchis, R. et al. Baveno VII – Renewing consensus in portal hypertension. J. Hepatol. 76, 959–974 (2022).
Villanueva, C. et al. beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 393, 1597–1608 (2019).
Villanueva, C. et al. Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis. J. Hepatol. 77, 1014–1025 (2022).
Turco, L., Reiberger, T., Vitale, G. & La Mura, V. Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension. Liver Int. 43, 1183–1194 (2023).
Mandorfer, M. et al. Nonselective beta blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology 146, 1680–1690.e1681 (2014).
Serste, T. et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 52, 1017–1022 (2010).
Cales, P. et al. Non-selective beta-blockers increase overall and liver mortality in alcoholic cirrhosis with MELD >/= 12 over 5 years of follow-up. Liver Int. 41, 168–179 (2021).
Thevenot, T., Mouhat, B., Cervoni, J. P. & Chopard, R. The dual role of non-selective beta-blockers in cirrhotic patients: How do we know when Dr Jekyll turns into Mr Hyde? Liver Int. 41, 1166–1167 (2021).
Villanueva, C. et al. Improving primary prophylaxis of variceal bleeding by adapting therapy to the clinical stage of cirrhosis. A competing-risk meta-analysis of individual participant data. Aliment Pharm. Ther. 59, 306–321 (2024).
Intagliata, N. M. et al. Procedural-Related Bleeding in Hospitalized Patients With Liver Disease (PROC-BLeeD): An International, Prospective, Multicenter Observational Study. Gastroenterology 165, 717–732 (2023).
Garcia-Tsao, G., Abraldes, J. G., Berzigotti, A. & Bosch, J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology 65, 310–335 (2017).
Izzy, M. et al. Redefining Cirrhotic Cardiomyopathy for the Modern Era. Hepatology 71, 334–345 (2020).
Swanson, K. L., Wiesner, R. H., Nyberg, S. L., Rosen, C. B. & Krowka, M. J. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am. J. Transpl. 8, 2445–2453 (2008).
DuBrock, H. M. et al. Outcomes of Liver Transplantation in Treated Portopulmonary Hypertension Patients With a Mean Pulmonary Arterial Pressure >/=35 mm Hg. Transpl. Direct 6, e630 (2020).
Sadd, C. J. et al. Long-term Outcomes and Survival in Moderate-severe Portopulmonary Hypertension After Liver Transplant. Transplantation 105, 346–353 (2021).
DuBrock, H. M., Del Valle, K. T. & Krowka, M. J. Mending the Model for End-Stage Liver Disease: An in-depth review of the past, present, and future portopulmonary hypertension Model for End-Stage Liver Disease exception. Liver Transpl. 28, 1224–1230 (2022).
Kim, N. H. et al. Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies. Pulm. Ther. 10, 85–107 (2024).
O’Leary, J. M., et al. Lack of a Tricuspid Regurgitation Doppler Signal and Pulmonary Hypertension by Invasive Measurement. J. Am. Heart Assoc. 7, e009362 (2018)
Kleb, C. et al. Liver Transplant Outcomes in Patients With Postcapillary Pulmonary Hypertension. Transpl. Direct 8, e1372 (2022).
Forde, K. A. et al. Pulse Oximetry Is Insensitive for Detection of Hepatopulmonary Syndrome in Patients Evaluated for Liver Transplantation. Hepatology 69, 270–281 (2019).
Porres-Aguilar, M., Altamirano, J. T., Torre-Delgadillo, A., Charlton, M. R. & Duarte-Rojo, A. Portopulmonary hypertension and hepatopulmonary syndrome: a clinician-oriented overview. Eur. Respir. Rev. 21, 223–233 (2012).
Singal, A. K. et al. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation 95, 755–760 (2013).
Kuo, H. T. et al. Risk factors for new-onset diabetes mellitus in adult liver transplant recipients, an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing database. Transplantation 89, 1134–1140 (2010).
Addepally, N. S. et al. Hemoglobin A1c Has Suboptimal Performance to Diagnose and Monitor Diabetes Mellitus in Patients with Cirrhosis. Dig. Dis. Sci. 63, 3498–3508 (2018).
Mantovani, A., et al. Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials. Metabolites, 11, 73 (2021).
Janicko, M., Veseliny, E., Lesko, D. & Jarcuska, P. Serum cholesterol is a significant and independent mortality predictor in liver cirrhosis patients. Ann. Hepatol. 12, 581–587 (2013).
Kaplan, D. E. The Use of Statins in Patients With Cirrhosis. Gastroenterol. Hepatol. 14, 485–487 (2018).
Pose, E. et al. Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Gastroenterol. Hepatol. 5, 31–41 (2020).
Pariente, E. A., Bataille, C., Bercoff, E. & Lebrec, D. Acute effects of captopril on systemic and renal hemodynamics and on renal function in cirrhotic patients with ascites. Gastroenterology 88, 1255–1259 (1985).
Gentilini, P. et al. Effects of low-dose captopril on renal hemodynamics and function in patients with cirrhosis of the liver. Gastroenterology 104, 588–594 (1993).
McAvoy, N. C., Kochar, N., McKillop, G., Newby, D. E. & Hayes, P. C. Prevalence of coronary artery calcification in patients undergoing assessment for orthotopic liver transplantation. Liver Transpl. 14, 1725–1731 (2008).
Bhatti, S. et al. Use of Computed Tomography Coronary Calcium Score for Coronary Artery Disease Risk Stratification During Liver Transplant Evaluation. J. Clin. Exp. Hepatol. 12, 319–328 (2022).
Fussner, L. A. et al. Cardiovascular disease after liver transplantation: When, What, and Who Is at Risk. Liver Transpl. 21, 889–896 (2015).
Albeldawi, M. et al. Cumulative risk of cardiovascular events after orthotopic liver transplantation. Liver Transpl. 18, 370–375 (2012).
Johnston, S. D., Morris, J. K., Cramb, R., Gunson, B. K. & Neuberger, J. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 73, 901–906 (2002).
Hughes, D. L. et al. Presence of any degree of coronary artery disease among liver transplant candidates is associated with increased rate of post-transplant major adverse cardiac events. Clin. Transpl. 34, e14077 (2020).
Rachwan, R. J. et al. CAD-LT score effectively predicts risk of significant coronary artery disease in liver transplant candidates. J. Hepatol. 75, 142–149 (2021).
Azarbal, B. et al. Feasibility and safety of percutaneous coronary intervention in patients with end-stage liver disease referred for liver transplantation. Liver Transpl. 17, 809–813 (2011).
Hughes, D. L. et al. Positron emission tomography myocardial perfusion imaging (PET MPI) findings predictive of post-liver transplant major adverse cardiac events. Liver Transpl. 29, 970–978 (2023).
Valgimigli, M. et al. Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. N. Engl. J. Med. 385, 1643–1655 (2021).
Wong, F. et al. Impact of Chronic Kidney Disease on Outcomes in Cirrhosis. Liver Transpl. 25, 870–880 (2019).
Wong, F. et al. Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut 60, 702–709 (2011).
Angeli, P., Garcia-Tsao, G., Nadim, M. K. & Parikh, C. R. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J. Hepatol. 71, 811–822 (2019).
Tan, H. K., Marquez, M., Wong, F. & Renner, E. L. Pretransplant Type 2 Hepatorenal Syndrome Is Associated With Persistently Impaired Renal Function After Liver Transplantation. Transplantation 99, 1441–1446 (2015).
Cannon, R. M. et al. Early Outcomes With the Liver-kidney Safety Net. Transplantation 105, 1261–1272 (2021).
Jay, C. L. et al. Difference in Survival in Early Kidney after Liver Transplantation Compared with Simultaneous Liver-Kidney Transplantation: Evaluating the Potential of the “Safety Net. J. Am. Coll. Surg. 230, 463–473 (2020).
Rosenblatt, R. et al. Equitable Access to Liver Transplant: Bridging the Gaps in the Social Determinants of Health. Hepatology 74, 2808–2812 (2021).
Shroff, H. & Kulik, L. Telemedicine for Liver Transplant Evaluations: The Benefits and Risks. Clin. Liver Dis. 19, 157–160 (2022).
Yang, J. et al. Travel distance and social vulnerability index: Impact on liver-related mortality among patients with end-stage liver disease. Clin. Transpl. 37, e15001 (2023).
Goldberg, D., Ross-Driscoll, K. & Lynch, R. County Differences in Liver Mortality in the United States: Impact of Sociodemographics, Disease Risk Factors, and Access to Care. Gastroenterology 160, 1140–1150.e1141 (2021).
Wahid, N. A., Rosenblatt, R. & Brown, R. S. Jr. A Review of the Current State of Liver Transplantation Disparities. Liver Transpl. 27, 434–443 (2021).
Deutsch-Link, S. et al. Racial and ethnic disparities in psychosocial evaluation and liver transplant waitlisting. Am. J. Transpl. 23, 776–785 (2023).
Henson, J. B., Chan, N. W., Wilder, J. M., Muir, A. J. & McElroy, L. M. Characterization of social determinants of health of a liver transplant referral population. Liver Transpl. 29, 1161–1171 (2023).
Duarte-Rojo, A. et al. Exercise and physical activity for patients with end-stage liver disease: Improving functional status and sarcopenia while on the transplant waiting list. Liver Transpl. 24, 122–139 (2018).
Kwong, A. J. et al. OPTN/SRTR 2021 Annual Data Report: Liver. Am. J. Transpl. 23, S178–S263 (2023).
Goldberg, D. et al. Underreporting of liver transplant waitlist removals due to death or clinical deterioration: results at four major centers. Transplantation 96, 211–216 (2013).
Kardashian, A. et al. Identifying an Optimal Liver Frailty Index Cutoff to Predict Waitlist Mortality in Liver Transplant Candidates. Hepatology 73, 1132–1139 (2021).
Cox-Flaherty, K. et al. Six-Minute walk distance predicts outcomes in liver transplant candidates. Liver Transpl. 29, 521–530 (2023).
Puchades, L. et al. Waiting time dictates impact of frailty: A Spanish multicenter prospective study. JHEP Rep. 5, 100840 (2023).
Lai, J. C. et al. Frailty, mortality, and health care utilization after liver transplantation: From the Multicenter Functional Assessment in Liver Transplantation (FrAILT) Study. Hepatology 75, 1471–1479 (2022).
Lai, J. C. et al. Changes in frailty are associated with waitlist mortality in patients with cirrhosis. J. Hepatol. 73, 575–581 (2020).
Dang, T. T. et al. The 6-Minute Walk Test Distance Predicts Mortality in Cirrhosis: A Cohort of 694 Patients Awaiting Liver Transplantation. Liver Transpl. 27, 1490–1492 (2021).
Lai, J. C. et al. Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 74, 1611–1644 (2021).
Lai, J. C. et al. Frailty in liver transplantation: An expert opinion statement from the American Society of Transplantation Liver and Intestinal Community of Practice. Am. J. Transpl. 19, 1896–1906 (2019).
Stine, J. G., et al. American College of Sports Medicine (ACSM) International Multidisciplinary Roundtable report on physical activity and nonalcoholic fatty liver disease. Hepatol. Commun. 7, e0108 (2023)
Macias-Rodriguez, R. U. et al. Changes in Hepatic Venous Pressure Gradient Induced by Physical Exercise in Cirrhosis: Results of a Pilot Randomized Open Clinical Trial. Clin. Transl. Gastroenterol. 7, e180 (2016).
Berzigotti, A. et al. Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study. Hepatology 65, 1293–1305 (2017).
Jamali, T. et al. Outcomes of Exercise Interventions in Patients With Advanced Liver Disease: A Systematic Review of Randomized Clinical Trials. Am. J. Gastroenterol. 117, 1614–1620 (2022).
Tandon, P. et al. Exercise in cirrhosis: Translating evidence and experience to practice. J. Hepatol. 69, 1164–1177 (2018).
Tapper, E. B., Martinez-Macias, R. & Duarte-Rojo, A. Is Exercise Beneficial and Safe in Patients with Cirrhosis and Portal Hypertension? Curr. Hepatol. Rep. 17, 175–183 (2018).
Lin, F. P. et al. Low Daily Step Count Is Associated With a High Risk of Hospital Admission and Death in Community-Dwelling Patients With Cirrhosis. Clin. Gastroenterol. Hepatol. 20, 1813–1820.e1812 (2022).
Duarte-Rojo, A. et al. Introducing EL-FIT (Exercise and Liver FITness): A Smartphone App to Prehabilitate and Monitor Liver Transplant Candidates. Liver Transpl. 27, 502–512 (2021).
Duarte-Rojo, A. et al. Use of a Mobile-Assisted Telehealth Regimen to Increase Exercise in Transplant Candidates: A Home-Based Prehabilitation Pilot and Feasibility Trial. Clin. Transl. Gastroenterol. 14, e00601 (2023).
Lin, F. P. et al. Prehabilitation-Driven Changes in Frailty Metrics Predict Mortality in Patients With Advanced Liver Disease. Am. J. Gastroenterol. 116, 2105–2117 (2021).
Ruiz-Margain, A. et al. Phase Angle From Bioelectrical Impedance for the Assessment of Sarcopenia in Cirrhosis With or Without Ascites. Clin. Gastroenterol. Hepatol. 19, 1941–1949 e1942 (2021).
Robinson, S. M. et al. Does nutrition play a role in the prevention and management of sarcopenia? Clin. Nutr. 37, 1121–1132 (2018).
Salim, T., Stark, S. A., Duarte-Rojo, A. Food as therapy for frailty. Curr. Hepatol. Rep. 19, 23–29 (2020).
Diwan, T. S. et al. Obesity, transplantation, and bariatric surgery: An evolving solution for a growing epidemic. Am. J. Transpl. 20, 2143–2155 (2020).
